[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659405":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":15,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":16,"locations":22,"responsibleParty":39,"collaborators":11,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":11,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":11,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":25,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Survival",null,"20 years",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":6,"maskingInfo":11},"COHORT","Patients 16 years of age and older, diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis, followed at Policlinico Hospital (MIlan, Italy)",[17],{"name":18,"role":19,"phone":20,"phoneExt":11,"email":21},"Barbara Mora, MD","CONTACT","+39 0255033345","barbara.mora@policlinico.mi.it",[23],{"facility":24,"status":25,"city":26,"state":11,"zip":11,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Ospedale Maggiore Policlinico","RECRUITING","Milan","Italy","IT",{"type":30,"coordinates":31},"Point",[32,33],9.18951,45.46427,{"lat":33,"lon":32},[36],{"name":37,"role":19,"phone":38,"phoneExt":11,"email":21},"Barbara Mora","+390255033345",{"type":40,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100659405","mpndpoint-single-center-retrospective-prospective-study-of-the-outcome-of-patients-with-philadelphia-negative-chronic-myeloproliferative-neoplasms-100659405",false,"NCT07863466","MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* Patients 16 years of age and older\n* Patients diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis (Arber et al, Blood 2022 or earlier but reclassified classifications)\n\nExclusion Criteria:\n\n* Patients with diagnosis other than polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis\n* Follow up of less than 6 months","ALL","16 Years",{"count":50,"type":51},1190,"ESTIMATED","OBSERVATIONAL","Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation into secondary acute myeloid leukemia. MPNs include: myelofibrosis, polycythemia vera, and essential thrombocythemia. The low incidence, comparable to that of rare diseases, induces the in-depth study of patients and thus the need to develop a project with databases to collect clinical, biological, and therapeutic information.",[55,56,57],"Myelofibrosis (MF)","Polycythemia Vera","Essential Thrombocythaemia",[59,56,60],"Myelofibrosis","Essential Thrombocythemia","2026-10-02",{"date":63,"type":64},"2026-10-07","ACTUAL",{"date":66,"type":64},"2025-02-17",{"date":68,"type":51},"2044-06",{"name":5,"class":6},1]